p53 and prognosis in colorectal cancer

Annals of the Academy of Medicine Singapore

Volumn 25, Issue 1, 1996, Pages 107-112

  Smith, D R ^a   Goh, H S ^b  

^a SINGAPORE GENERAL HOSPITAL   (Singapore)

^b Gleneagles Medical Centre

Author keywords

Prognostic indicator; Tumour suppressor

Indexed keywords

TUMOR MARKER;

ADENOCARCINOMA; APOPTOSIS; COLORECTAL TUMOR; GENETICS; HUMAN; MORTALITY; PHYSIOLOGY; POINT MUTATION; PROGNOSIS; REVIEW; TUMOR SUPPRESSOR GENE;

ADENOCARCINOMA; APOPTOSIS; COLORECTAL NEOPLASMS; GENES, P53; HUMANS; POINT MUTATION; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 0029689349     PISSN: 03044602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (97)

1. Chapuis P H, Dent O F, Fisher R, Newland R C, Pheils M T, Smyth E, et al. A multivariate analysis of clinical and pathological variables in prognosis after resection of large bowel cancer. Br J Surg 1985; 72:698-702.
2. Lane D P, Crawford L. T antigen is bound to a host protein in SV40 transformed cells. Nature 1979; 278:261-3.
3. Linzer D I H, Levine A J Characterisation of a 54K dalton cellular SV40 rumor antigen present in SV40 transformed cells and uninfected embryonal carcinoma cells. Cell 1979; 17:43-52.
4. Sarnow P, Ho Y S, Williams J, Levine A J. Adenovirus E1b-58 kd rumor antigen and SV40 large tumor antigen are physically associated with the same 54 kd cellular protein in transformed cells. Cell 1982, 28:387-94.
5. Isobe M, Emanuel B S, Givol D, Oren M, Croce C. Localisation of the gene for human p53 tumor antigen to band 17p13. Nature 1986, 320:84-5.
6. McBride O W, Merry D, Givol D. The gene for human p53 cellular tumor antigen is located on chromosome 17 short arm (17p13). Proc Natl Acad Sci USA 1986; 83:130-4.
7. Lamb P, Crawford L Characterisation of the human p53 gene. Mol Cell Biol 1986; 6 1379-85.
8. Lane D P, Benchimol S. p53: Oncogene or antioncogene? Genes Dev 1990; 4:1-8.
9. Rogel A, Popliker M, Webb C G, Oren M. p53 cellular tumor antigen: analysis of mRNA levels in normal adult tissues, embryos and rumors. Mol Cell Biol 1985; 5.2851-5.
10. Bisschoff J R, Friedman P N, Marshak D R, Prives C, Beach D. Human p53 is phosphorylated by p60-cdc2 and cyclin B-cdc2. Proc Natl Acad Sci USA 1990; 87:4766-70.
11. Sturbegner K W, Maimets T, Chumakov P, Brain R, Addison C, Simanis V, et al. p53 interacts with p34cdc2 in mammalian cells, implications for cell cycle control and oncogenesis. Oncogene 1990, 5:795-801.
12. Meek D W, Simon S, Kikkawa U, Eckhart W. The p53 tumor suppressor protein is phosphorylated at serine 389 by casein kirtase II. EMBO J 1990, 9.3253-60.
13. Baker S, Markowitz S, Fearon E, Wilsson J, Vogelstein B. Suppression of human colorectal carcinoma cell growth by wild type p53. Science 1990a; 249.912-5.
14. Diller L, Kassel J, Nelson C E, Gryka M A, Litwak G, Gebhardt M, et al. p53 functions as a cell cycle control protein in osteosarcomas. Mol Cell Biol 1990; 10:5775-81.
15. Mercer W E, Shields M T, Amin M, Sauve G J, Appella E, Romano J W, et al. Negative growth regulation in a glioblastoma tumor cell line that conditionally expresses human wild-type p53. Proc Natl Acad Sci USA 1990; 87:6166-70.
16. Michalovitz D, Halevy O, Oren M. Conditional inhibition of transformation and of cell proliferation by a temperature-sensitive mutant p53. Cell 1990; 62:671-80
17. Martinez J, Georgoff I, Martinez J, Levine A J Cellular localization and cell cycle regulation by a temperature sensitive p53 protein. Genes Dev 1990; 5:151-9.
18. Fields S, Jang S K. Presence of a potent transcription activating sequence in the p53 protein. Science 1990; 249 1046-9.
19. Raycroft L, Wu H, Lozano G. Transcriptional activation by wild type but not transforming mutants of the p53 anti-oncogene. Science 1990; 249:1049-51.
20. O'Rourke R W, Miller C W, Kato G J, Simon K J, Chen D-L, Dang C V, et al. A potent transcriptional activation element m the p53 protein. Oncogene 1990; 5:1829-32.
21. Lane D P, Gannon J H. Cellular proteins involved in SV40 transformation. Cell Biol Int Rep 1983; 7.513-4.
22. Steinmeyer K, Deppert W. DNA binding properties of murine p53 Oncogene 1988; 3:501-7.
23. Kern SE, Kinzer K W, Baker S J, Nigro J M, Rotter V, Levine A J, et al. Mutant p53 proteins bind DNA abnormally in vitro. Oncogene 1991; 6:131-6.
24. Zambetti G P, Bargonetti J, Walker K, Prives C, Levine A J Wild type p53 mediates positive regulation of gene expression through a specific DNA sequence element. Genes Dev 1992; 6:1143-52.
25. Farmer G, Bargonetti J, Zhu H, Friedman P, Prywes R, Prives C Wild type p53 activates transcription in vitro. Nature 1992; 385:83-6.
26. Chen P, Chen Y, Bookstein R, Lee W. Genetic mechanisms of tumor suppression by the human p53 gene. Science 1990; 250:1576-80.
27. Baker S J, Fearon E R, Nigro J M, Hamilton S R, Preisinger A C, Jessup J M, et al. Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science 1989; 244:217-20.
28. Nigro J M, Baker S J, Preisinger A C, Jessup J M, Hostetter R, Cleary K, et al. Mutations in the p53 gene occur in diverse human tumor types. Nature 1989; 342.705-8
29. Takahashi T, Nau M M, Chiba I, Birrer M J, Rosenberg R K, Vinocour M, et al. p53: a frequent target for genetic abnormalities in lung cancer. Science 1989, 246:491-4.
30. Mulligan L M, Matlashewski G J, Scrable H J, Cavenee W K. Mechanism of p53 loss in human sarcomas Proc Natl Acad Sci USA 1990; 87:5863-7
31. Baker S J, Preisinger A C, Jessup J M, Paraskeva C, Markowitz S, Wilson J K V, et al. p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis. Cancer Res 1990b; 50:7717-22.
32. Hinds P, Finlay C, Levine A J. Mutation is required to activate the p53 gene for cooperation with the ras oncogene and transformation. J Virol 1989; 63:739-46.
33. Hinds P W, Finlay C A, Quartin R S, Baker S J, Fearon E R, Vogelstein B, et al. Mutant p53 DNA clones from human colon carcinomas cooperate with res in transforming primary rat cells: a comparison of the "hot spot" mutant phenotypes. Cell Growth Differ 1990; 1:571-80
34. Jenkins J R, Rudge K, Currie G A. Cellular immortalisation by a cDNA clone encoding the transformation associated phosphoprotein p53. Nature 1984; 312:651-4.
35. Rovinski B, Benchimol S Immortalization of rat embryo fibroblasts by the cellular p53 oncogene. Oncogene 1988, 2:445-52.
36. Eliyahu D, Raz A, Gruss P, Givol D, Oren M. Participation of p53 cellular tumor antigen in transformation of normal and embryonic cells. Nature 1984; 312.646-9.
37. Parada L, Land H, Weinberg R, Wolf D, Rotter V. Cooperation between gene encoding p53 tumor antigen and ras in cellular transformation. Nature 1984, 312:649-51
38. Finlay C A, Hinds P W, Levine A J. The p53 protooncogene can act as a suppressor of transformation. Cell 1989; 57.1083-93.
39. Ehyahu D, Michalovitz D, Eliyahu S, Pinhashi-Kimhi O, Oren M. Wild type p53 can inhibit oncogene mediated focus formation. Proc Natl Acad Sci USA 1989, 86:8763-7.
40. Halevy O, Michaloviyz D, Oren M Different tumor derived p53 mutants exhibit distinct biological activities. Science 1990; 250:113-6
41. Donehower L A, Harvey M, Slagle B L, McArthur M J, Montgomery C A, Butel J S, et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumors. Nature 1992; 356:215-21.
42. Hollstein M, Sidransky D, Vogelstein B, Harris C. p53 mutations in human cancers. Science 1991, 253:49-53.
43. Levine A J, Momand J, Finlay C A. The p53 tumor suppressor gene. Nature 1991; 351:453-6.
44. Vogelstein B. A deadly inheritance. Nature 1990; 348:681-2.
45. Iggo R, Gatter K, Bartek J, Lane D, Harris A. Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet 1990; 335:675-9.
46. Malkin D, Li F, Strong L, Fraumeni J, Nelson C, Kim D, et al. Germline p53 mutations in a familial syndrome of breast cancer, sarcomas and other neoplasms. Science 1990; 250:1233-8.
47. Bressac B, Kew M, Wands J, Ozturk M. Selective G to T mutations of p53 gene in hepatocellular carcinoma from Southern Africa. Nature 1991; 350 429-31.
48. Hsu I, Metcalf R, Sun T, Welsh J, Wang N, Harris C. Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature 1991; 350:427-8
49. Rady P, Scinicariello F, Wagner R K, Tyring S K. p53 mutations in basal cell carcinomas. Cancer Res 1992; 52.3804-6.
50. Sidransky D, von Eschenbach A, Tsai Y C, Jones P, Summerhayes I, Marshall F, et al. Identification of p53 gene mutations in bladder cancers and urine samples. Science 1991; 252:706-9.
51. Oren M. The cellular p53 cellular tumor antigen: gene structure, expression and protein. Biochem Biophys Acta 1985; 823:67-78
52. Gronostajski R M, Goldberg A J, Pardee A B. Energy requirement for degradation of tumour-associated protein p53. Mol Cell Biol 1984; 3:442-8.
53. Reich N C, Oren M, Levine A J. Two distinct mechanisms regulate the level of a cellular tumour antigen, p53. Mol Cell Biol 1983; 3:2143-50.
54. Oren M, Maltzman W, Levine A J. Post translational regulation of the 54K cellular rumor antigen in normal and transformed cells. Mol Cell Biol 1981; 1:101-10.
55. Finlay C A, Hinds P W, Tan T-H, Eliyaha D, Oren M, Levine A J. Activating mutations for transformation by p53 produce a gene product that forms a hsc70-p53 complex with an altered half-life. Mol Cell Biol 1988; 8:531-9.
56. Sturzbecher H-W, Chumakov P, Welch W J, Jenkins J R Mutant p53 proteins bind hsp 72/73 cellular heat shock-related proteins in SV40 transformed monkey cells. Oncogene 1987; 1:201-11.
57. Rodriguez N R, Rowan A, Smith M E F, Kerr I B, Bodmer W F, Gannon J V, et al p53 mutations in colorectal cancer. Proc Natl Acad Sci USA 1990; 87:7555-9.
58. Bartek J, Iggo R, Gannon J, Lane D. Genetic and immunochemical analysis of mutant p53 in human breast cancer cell lines. Oncogene 1990; 5:893-9.
59. Van Den Berg F M, Tigges A J, Schipper M E I, Den Harog-Jayer F C A, Kroes W G, et al. Expression of the nuclear oncogene p53 in colon tumours. J Pathol 1989; 157:193-9.
60. Eccles D M, Brett L, Lessells A, Gruber L, Lane D, Steel C M, et al. Overexpression of the p53 protein and allele loss at 17p13 in ovarian carcinomas. Br J Cancer 1992; 65:40-4.
61. Bartek J, Bartkova J, Vojtesek B, Staskova Z, Lukas J, Rejthar A, et al. Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies. Oncogene 1991; 6:1699-703.
62. Cunningham J, Lust J A, Schaid D J, Bren G D, Carpenter H A, Rizza E, et al. Expression of p53 and 17p allelic loss in colorectal carcinoma. Cancer Res 1992; 52:1974-80.
63. Cook A, Mimer J. Evidence for allosteric variants of wild type p53, a tumour suppressor protein. Br J Cancer 1990; 61:548-52.
64. Banks L, Matiachewski G, Crawford L. Isolation of human-p53-specific monoclonal antibodies and their use in studies of human p53 expression Eur J Biochem 1989; 159.529-34.
65. Gannon J V, Greaves R V, Iggo R, Lane D P Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. EMBO J 1990, 9:1595-602.
66. Scott N, Sagar P, Stewart J, Blair G E, Dixon H F, Quirke P. p53 in colorectal cancer: clinicopathological correlation and prognostic significance. Br J Cancer 1991; 63:317-9.
67. Crawford L V, Pim D C, Lamb P. The cellular protein p53 in human tumours. Mol Biol Med 1984; 2:261-72
68. Starzynska T, Bromley M, Ghosh A, Stern P L. Prognostic significance of p53 overexpression in gastric and colorectal carcinoma. Br J Cancer 1992; 66:558-62.
69. Bell SM, Scott N, Cross D, Sagar P, Lewis F A, Blair G E, et al. Prognostic value of p53 over-expression and c-Ki-ras gene mutations in colorectal cancer. Gastroenterology 1993; 104:57-64.
70. Yamaguchi A, Kuraka Y, Fushida S, Kanno M, Yonemura Y, Miwa K, et al. Expression of the p53 protein in colorectal cancer and its relationship to short term prognosis. Cancer 1992; 70 2778-84
71. Remvikos Y, Tominaga O, Hammel P, Laurent-Puig P, Salmon R J, Dutrillaux B, et al. Increased p53 protein content of colorectal tumours correlates with poor survival. Br J Cancer 1992, 66:758-64.
72. Bosari S, Viale G, Bossi P, Maggioni M, Coggi G, Murray J J, et al Cytoplasmic accumulation of p53 protein: an independent prognostic indicator of colorectal adenocarcinomas J Natl Cancer Inst 1994; 86:681-7.
73. Sun X-F, Carstensen J M, Zhang H, Stal O, Wingren S, Hatschek T, et al Prognostic significance of cytoplasmic p53 oncoprotein in colorectal adenocarcinoma. Lancet 1992; 340:1369-73.
74. Nathanson S D, Linden M D, Tender P, Zarbo R J, Jacobson G, Nelson L S. Relationship among p53, stage and prognosis of large bowel cancer. Dis Colon Rectum 1994; 37:527-34.
75. Smith D R, Ji C-Y, Goh H-S p53 and prognosis in colorectal cancer. Br J Cancer 1996. (In press)
76. Goh H-S, Chan C-S, Khine K, Smith D R. p53 and behaviour of colorectal cancer Lancet 1994; 344:233-4
77. Vogelstein B. p53 function and dysfunction. Cell 1992; 70:523-6.
78. Jego N, Thomas G, Hamelin R. Short direct repeats flanking deletions, and duplicating insertions in p53 gene in human cancers. Oncogene 1993; 8:209-13
79. Marshall C J. Tumour suppressor genes. Cell 1991; 64:313-26.
80. Vogelstein B, Fearon E R, Hamilton S R, Kern S E, Preisinger A C, Leppert M, et al. Genetic alterations during colorectal tumour development. N Engl J Med 1988; 319:525-32.
81. Vogelstein B, Fearon E R, Kern S E, Hamilton S R, Preisinger A C, Nakamura Y, et al. Allelotype of colorectal carcinomas Science 1989; 244:207-11.
82. Delattre O, Olschwang S, Law D J, Melot T, Remivkos Y, Salmon R J, et al. Multiple genetic alterations in distal and proximal colorectal cancer. Lancet 1989; 2:353-6.
83. Kern S E, Fearon E R, Tersmette K W F, Enterline J P, Leppert M, Nakamura Y, et al. Allelic loss in colorectal cancer. JAMA 1989; 261:3099-103.
84. Khine K, Smith D R, Goh H-S. High frequency of allelic deletion on chromosome 17p in advanced colorectal cancer Cancer 1994; 73:28-35.
85. Laurent-Puig P, Olshwang S, Delattre O, Remvikos Y, Asselain B, Melot T, et al. Survival and acquired genetic alterations in colorectal cancer. Gastroenterology 1992; 102:1136-41.
86. O'Connell M J, Schaid D J, Ganju V, Cunningham J, Kovach J S, Thibodeau S N. Current status of adjuvant chemotherapy for colorectal cancer. Cancer 1992; 70:1732-9.
87. Campo E, Miguel R, Jares P, Bosch F, Juan M, Leone A, et al. Prognostic significance of the loss of heterozygosity of Nm23-H1 and p53 genes in human colorectal cancer. Cancer 1994; 73:2913-21
88. Khine K, Goh H-S, Smith D R. Prognostic significance of chromosome 5q and 17p allelic deletion in colorectal cancer. Int J Oncol 1995; 7:631-5.
89. Hamelin R, Laurent-Puig P, Olschwang S, Jego N, Asselain B, Remvikos Y, et al. Association of p53 mutations with short survival in colorectal cancer. Gastroenterology 1994; 106:42-8.
90. Goh H-S, Yao Y, Smith D R. p53 point mutation and survival in colorectal cancer patients. Cancer Res 1995; 55 5217-21.
91. Kronborg O. Staging and surgery for colorectal cancer. Eur J Cancer 1993; 29A:575-83.
92. Kerr J F R, Winterfod C M, Harmon B V. Apoptosis: Its significance in cancer and cancer therapy Cancer 1994; 73:2013-26.
93. Lowe S W, Ruley H E, Jacks T, Houseman D E. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents Cell 1993; 74:957-67.
94. Shaw P, Bovey R, Tardy S, Sahli R, Sordat B, Costa J. Induction of apoptosis by wild type p53 in a human colon tumour derived cell line Proc Natl Acad Sci USA 1992; 89:4495-9.
95. Lowe S, Bodis S, McClatchey A, Remington L, Ruley H E, Fisher D E, et al. p53 status and the efficiency of cancer therapy in vivo. Science 1994; 266:807-10.
96. Lane D P, Benchimol S. p53: Oncogene or antioncogene? Genes Dev 1990; 4:1-8.
97. Fearon E R, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990; 61:759-67.